| __timestamp | ADMA Biologics, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 22570000 |
| Thursday, January 1, 2015 | 6745968 | 24378000 |
| Friday, January 1, 2016 | 8494742 | 26621000 |
| Sunday, January 1, 2017 | 18092835 | 28653000 |
| Monday, January 1, 2018 | 22502922 | 37734000 |
| Tuesday, January 1, 2019 | 25910757 | 41884000 |
| Wednesday, January 1, 2020 | 35050817 | 64435000 |
| Friday, January 1, 2021 | 42896889 | 57483000 |
| Saturday, January 1, 2022 | 52458024 | 70062000 |
| Sunday, January 1, 2023 | 59020000 | 52790000 |
Unlocking the unknown
In the competitive landscape of biopharmaceuticals, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, ADMA Biologics, Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. ADMA Biologics has seen a remarkable increase, with expenses growing by over 1,100%, from approximately $4.8 million in 2014 to nearly $59 million in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Ligand Pharmaceuticals, while starting with higher expenses, saw a more moderate increase of about 134%, peaking in 2022 before a slight decline in 2023. This suggests a strategic shift towards efficiency and cost management. These trends highlight the differing strategies of these companies in navigating the dynamic biopharma sector.
SG&A Efficiency Analysis: Comparing Novartis AG and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Sanofi and ADMA Biologics, Inc.
Breaking Down SG&A Expenses: GSK plc vs ADMA Biologics, Inc.
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Walgreens Boots Alliance, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Galapagos NV